Drug intelligence / Profile preview

RAPA115

Development stage: Preclinical
Lead developer: HK inno.N Corporation
Modality: Small Molecules
Administration: Oral

Overview

RAPA115 is an orally available therapeutic agent under development by HK inno.N (formerly CJ HealthCare) for an undisclosed indication. As of the latest available information, specific details regarding its mechanism of action, molecular target, or clinical trial phase have not been publicly disclosed. There is no evidence that RAPA115 is related to sirolimus (Rapamune), despite the similarity in naming conventions[2].

Beyond the preview

Go deeper on RAPA115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAPA115.

Explore the full profile